Filing Flows › Artivion (AORT) › Q3 2026 › vs Q3 2025
Artivion (AORT) Q3 2026 vs Q3 2025 (year over year)
Artivion's revenue rose $10.4M (+9%) from $113M in Q3 2025 to $124M in Q3 2026. The biggest changes: Products +$10.5M (+12%); Preservation services −$93K (-0.4%).
Artivion, Q3 2026: revenue $124M (+9% year over year), operating margin 2.4%, net loss $7.9M, operating cash flow −$4.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Aortic stent grafts | $44.3M | $39.6M | $4.7M | +12% |
| On-X | $30.3M | $26.8M | $3.5M | +13% |
| Surgical sealants | $18.9M | $18.9M | $53K | +0.3% |
| Other | $4.6M | $2.4M | $2.2M | +93% |
| Products | $98.2M | $87.7M | $10.5M | +12% |
| Preservation services | $25.6M | $25.7M | −$93K | -0.4% |
| Revenue | $124M | $113M | $10.4M | +9% |
| Net loss | $7.9M | −$6.5M | $14.4M | — |
| Costs & expenses | $132M | $113M | $18.3M | +16% |
| Operating costs | $121M | $101M | $20.0M | +20% |
| Interest & other, net | $8.9M | $5.5M | $3.4M | +62% |
| Income tax | $2.0M | $554K | $1.5M | +262% |
| Cost of revenue | $47.8M | $39.0M | $8.8M | +23% |
| Operating cash sources | $18.1M | −$10.4M | $28.5M | — |
| Depreciation & amortization | $7.3M | $5.7M | $1.6M | +28% |
| Share-based compensation | $6.2M | $6.1M | $89K | +1% |
| Cash used in operations | $4.6M | −$22.3M | $26.8M | — |
| Net loss absorbed | $7.9M | −$6.5M | $14.4M | — |
| Working capital & other | $10.2M | −$3.9M | $14.1M | — |
Questions
How much did Artivion's revenue grow year over year in Q3 2026?
Artivion's revenue rose $10.4M (+9%) from $113M in Q3 2025 to $124M in Q3 2026.
What drove Artivion's revenue change in Q3 2026?
Products +$10.5M (+12%); Preservation services −$93K (-0.4%).